172 related articles for article (PubMed ID: 29188469)
1. MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
Yan SB; Um SL; Peek VL; Stephens JR; Zeng W; Konicek BW; Liu L; Manro JR; Wacheck V; Walgren RA
Invest New Drugs; 2018 Aug; 36(4):536-544. PubMed ID: 29188469
[TBL] [Abstract][Full Text] [Related]
2. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
[TBL] [Abstract][Full Text] [Related]
3. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
Rosen LS; Goldman JW; Algazi AP; Turner PK; Moser B; Hu T; Wang XA; Tuttle J; Wacheck V; Wooldridge JE; Banck M
Clin Cancer Res; 2017 Apr; 23(8):1910-1919. PubMed ID: 27803065
[No Abstract] [Full Text] [Related]
4. Acquired Resistance to a MET Antibody
Pollmann SE; Calvert VS; Rao S; Boca SM; Madhavan S; Horak ID; Kjaer A; Petricoin EF; Kragh M; Poulsen TT
Mol Cancer Ther; 2018 Jun; 17(6):1259-1270. PubMed ID: 29545332
[TBL] [Abstract][Full Text] [Related]
5. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
[TBL] [Abstract][Full Text] [Related]
6. Sym015: A Highly Efficacious Antibody Mixture against
Poulsen TT; Grandal MM; Skartved NJØ; Hald R; Alifrangis L; Koefoed K; Lindsted T; Fröhlich C; Pollmann SE; Eriksen KW; Dahlman A; Jacobsen HJ; Bouquin T; Pedersen MW; Horak ID; Lantto J; Kragh M
Clin Cancer Res; 2017 Oct; 23(19):5923-5935. PubMed ID: 28679766
[No Abstract] [Full Text] [Related]
7. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
8. A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.
Sakai D; Chung HC; Oh DY; Park SH; Kadowaki S; Kim YH; Tsuji A; Komatsu Y; Kang YK; Uenaka K; Wijayawardana SR; Wacheck V; Wang X; Yamamura A; Doi T
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1197-1207. PubMed ID: 29071414
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
10. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
Ebert K; Mattes J; Kunzke T; Zwingenberger G; Luber B
PLoS One; 2019; 14(9):e0223225. PubMed ID: 31557260
[TBL] [Abstract][Full Text] [Related]
11. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
12. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Salgia R; Sattler M; Scheele J; Stroh C; Felip E
Cancer Treat Rev; 2020 Jul; 87():102022. PubMed ID: 32334240
[TBL] [Abstract][Full Text] [Related]
13. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Yan SB; Peek VL; Ajamie R; Buchanan SG; Graff JR; Heidler SA; Hui YH; Huss KL; Konicek BW; Manro JR; Shih C; Stewart JA; Stewart TR; Stout SL; Uhlik MT; Um SL; Wang Y; Wu W; Yan L; Yang WJ; Zhong B; Walgren RA
Invest New Drugs; 2013 Aug; 31(4):833-44. PubMed ID: 23275061
[TBL] [Abstract][Full Text] [Related]
14. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.
Lee JM; Kim B; Lee SB; Jeong Y; Oh YM; Song YJ; Jung S; Choi J; Lee S; Cheong KH; Kim DU; Park HW; Han YK; Kim GW; Choi H; Song PH; Kim KA
Oncogene; 2014 Jan; 33(1):34-43. PubMed ID: 23208509
[TBL] [Abstract][Full Text] [Related]
15. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.
Gonzalez A; Broussas M; Beau-Larvor C; Haeuw JF; Boute N; Robert A; Champion T; Beck A; Bailly C; Corvaïa N; Goetsch L
Int J Cancer; 2016 Oct; 139(8):1851-63. PubMed ID: 27144973
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.
Srivastava AK; Hollingshead MG; Weiner J; Navas T; Evrard YA; Khin SA; Ji JJ; Zhang Y; Borgel S; Pfister TD; Kinders RJ; Bottaro DP; Linehan WM; Tomaszewski JE; Doroshow JH; Parchment RE
Clin Cancer Res; 2016 Jul; 22(14):3683-94. PubMed ID: 27001313
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
He AR; Cohen RB; Denlinger CS; Sama A; Birnbaum A; Hwang J; Sato T; Lewis N; Mynderse M; Niland M; Giles J; Wallin J; Moser B; Zhang W; Walgren R; Plimack ER
Oncologist; 2019 Sep; 24(9):e930-e942. PubMed ID: 30833489
[TBL] [Abstract][Full Text] [Related]
18. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
19. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring
Engstrom LD; Aranda R; Lee M; Tovar EA; Essenburg CJ; Madaj Z; Chiang H; Briere D; Hallin J; Lopez-Casas PP; Baños N; Menendez C; Hidalgo M; Tassell V; Chao R; Chudova DI; Lanman RB; Olson P; Bazhenova L; Patel SP; Graveel C; Nishino M; Shapiro GI; Peled N; Awad MM; Jänne PA; Christensen JG
Clin Cancer Res; 2017 Nov; 23(21):6661-6672. PubMed ID: 28765324
[No Abstract] [Full Text] [Related]
20. Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody.
Pupo E; Ducano N; Lupo B; Vigna E; Avanzato D; Perera T; Trusolino L; Lanzetti L; Comoglio PM
Cancer Res; 2016 Sep; 76(17):5019-29. PubMed ID: 27364553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
